GLP-1 weight-loss treatment no longer means choosing only between weekly injections. Wegovy is now available in both injectable and oral forms for adults with obesity or overweight plus a weight-related condition, giving patients two ways to take the same active drug, semaglutide. The two formulations target the same GLP-1 receptor, but they differ in dosing, absorption, convenience, and the strength of the evidence supporting direct comparisons.
The pill and the injection use the same molecule
Both formulations contain semaglutide, a glucagon-like peptide-1 receptor agonist. Semaglutide activates the GLP-1 receptor, which helps reduce appetite, increase satiety, slow gastric emptying, and improve glucose regulation.
The main difference is delivery. Injectable Wegovy delivers semaglutide into subcutaneous tissue once weekly. Wegovy tablets use an absorption enhancer called salcaprozate sodium, or SNAC, to help semaglutide cross the stomach lining after oral dosing.
Our GLP-1 drugs explainer covers the biology of the pathway in more detail.
Oral Wegovy is a daily treatment, not a weekly pill
The FDA-approved Wegovy tablet regimen starts at 1.5 mg once daily for 30 days, then increases every 30 days to 4 mg, 9 mg, and finally the 25 mg maintenance dose.
The tablet must be taken in the morning on an empty stomach with no more than 4 ounces of water. Patients are instructed to wait at least 30 minutes before eating, drinking other beverages, or taking other oral medications. The tablet should be swallowed whole and not split, crushed, chewed, or dissolved.
Injectable Wegovy is dosed once weekly. The usual maintenance dose is 2.4 mg weekly, although the label also includes other maintenance options and, since 2026, a 7.2 mg Wegovy HD injection for selected adults who need additional weight reduction.
OASIS 4 showed substantial weight loss with oral semaglutide 25 mg
The pivotal OASIS 4 trial enrolled 307 adults with obesity or overweight plus at least one weight-related complication who did not have diabetes. Participants were randomized 2:1 to oral semaglutide 25 mg or placebo once daily, both with lifestyle intervention.
At week 64, mean body weight decreased by 13.6% with oral semaglutide and 2.2% with placebo, an estimated treatment difference of 11.4 percentage points. Participants receiving oral semaglutide were also significantly more likely to achieve weight reductions of 5%, 10%, 15%, and 20%.
Gastrointestinal adverse events were common: 74.0% of participants taking oral semaglutide reported gastrointestinal events versus 42.2% with placebo. These were generally consistent with the known GLP-1 safety profile.
Injectable semaglutide produced similar-scale weight loss in STEP 1
The STEP 1 trial enrolled 1,961 adults with obesity or overweight plus at least one weight-related condition, also without diabetes. Participants received semaglutide 2.4 mg by weekly injection or placebo for 68 weeks, again with lifestyle intervention.
Mean body weight fell by 14.9% with semaglutide and 2.4% with placebo. In the semaglutide group, 86.4% of participants lost at least 5% of their starting weight, 69.1% lost at least 10%, and 50.5% lost at least 15%.
Those results helped establish injectable Wegovy as a major obesity treatment. Our semaglutide vs tirzepatide comparison places that magnitude of weight loss in the broader incretin landscape.
The trial numbers look similar, but they are not a head-to-head comparison
It is tempting to compare 13.6% weight loss with oral semaglutide against 14.9% with injectable semaglutide and conclude that the injection is slightly stronger. That would be an overinterpretation.
OASIS 4 and STEP 1 enrolled different participants, ran for different durations, and were conducted in different eras and settings. Even when eligibility criteria look similar, cross-trial comparisons cannot control for all differences in baseline characteristics, adherence, discontinuation, and trial conduct.
The FDA label notes that average semaglutide exposure with the 25 mg oral tablet is predicted to be comparable to the 2.4 mg weekly injection in adults with obesity or overweight, but exposure is more variable with oral dosing.
Why does the pill require a much larger dose?
The answer is absorption. Semaglutide is a peptide, and the gastrointestinal tract is designed to break peptides down. Only a small fraction of an oral dose reaches the bloodstream.
FDA pharmacokinetic data estimate oral semaglutide bioavailability at roughly 1% to 2%. That is why the daily oral maintenance dose is 25 mg even though the standard weekly injection is 2.4 mg.
The dose numbers therefore cannot be compared directly. A 25 mg tablet does not mean patients are receiving roughly ten times more active drug into circulation than with a 2.4 mg injection.
Convenience is not one-directional
For people who strongly dislike injections, a pill may remove one of the biggest barriers to starting treatment. Tablets also avoid needles, injection-site reactions, and storage or disposal issues associated with pens.
But oral dosing has its own burden. Wegovy tablets must be taken every morning under fasting conditions, with limited water, followed by a 30-minute wait before food, beverages, or other oral medications. A weekly injection may actually be simpler for people who struggle with daily medication routines.
That tradeoff means “pill versus injection” is not simply a question of which route sounds easier.
Safety is broadly similar because the active drug is the same
Both formulations carry the boxed warning about thyroid C-cell tumors observed in rodents and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Other important risks include pancreatitis, gallbladder disease, severe gastrointestinal adverse reactions, kidney injury related to volume depletion, hypersensitivity reactions, and delayed gastric emptying. Nausea, vomiting, diarrhea, constipation, abdominal pain, and related gastrointestinal effects remain among the most common adverse events.
Our GLP-1 side-effects guide reviews these issues in more detail.
Switching between the pill and injection is built into the FDA label
The current prescribing information specifically addresses switching between formulations. Patients taking Wegovy 2.4 mg weekly for weight reduction may switch to 25 mg tablets one week after stopping the injection.
Patients taking 25 mg tablets may switch to the 2.4 mg weekly injection the day after stopping the tablets. If the 25 mg tablet is not tolerated, the label says clinicians can consider switching to the 1.7 mg weekly injection.
That is an important practical signal: FDA treats the two formulations as alternative delivery strategies within the same Wegovy treatment platform rather than as completely separate therapies.
The pill does not eliminate the need for long-term treatment
Changing the route does not change the chronic nature of obesity treatment. When GLP-1 therapy is stopped, appetite and weight can move back toward pretreatment levels.
Our article on stopping GLP-1 drugs reviews the withdrawal evidence from semaglutide and tirzepatide trials.
What the evidence cannot yet answer
There is no large randomized head-to-head trial directly comparing approved oral Wegovy 25 mg with approved injectable Wegovy 2.4 mg in the same population. That is the biggest limitation when discussing whether one formulation is more effective.
OASIS 4 was also smaller than STEP 1, enrolling 307 participants versus 1,961, and 93% of participants in the oral semaglutide safety population were White. That limits certainty about how well the trial represents more diverse populations.
Both OASIS 4 and STEP 1 were funded by Novo Nordisk, the manufacturer of Wegovy, and several investigators were company employees or had industry relationships. The randomized designs strengthen the efficacy findings, but independent comparative effectiveness data would still be valuable.
The choice is increasingly about fit, not just efficacy
The arrival of oral Wegovy changes the practical question from “Will patients accept injections?” to “Which delivery method fits this person’s routine, preferences, medical history, and ability to adhere?”
For now, the evidence supports both oral and injectable semaglutide as effective obesity treatments. The pill offers a needle-free option with weight loss in the same broad range seen with the injection, but without a direct head-to-head trial, claims of superiority should be avoided.
References
- Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025;393:1077-1087. DOI: 10.1056/NEJMoa2500969.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002. DOI: 10.1056/NEJMoa2032183.